Clinical Trial Update: A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Pfizer's Phase 1 study of PF-03084014 in Japanese patients with advanced solid tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• PF-03084014 (nirogacestat)

Snippet

Sponsor: Pfizer | Conditions: Advanced Solid Tumors | Phase 1 | Status: WITHDRAWN